2025 年 08 月 24 日 机构力量增强是趋势，紧抓本轮行 情 AI+中国创新主线 ——北交所策略周报（20250818-20250824） 证券分析师 刘靖 A0230512070005 liujing@swsresearch.com 王雨晴 A0230522010003 wangyq@swsresearch.com 本周策略观点： 本周市场行情： ⚫ 市场：本周北证 50 指数上涨 8.40%。北交所个股中 247 只股票上涨，万通液压、海达 尔涨幅居前。25 只股票下跌，1 只股票持平，涨跌比为 9.88。估值：北交所 PE（TTM） 均值 97.42 倍，中值 56.05 倍；创业板 PE（TTM）均值 93.23 倍，中值 41.39 倍；科创 板 PE（TTM）均值 96.01 倍，中值 39.65 倍。交易：本周北交所成交量为 81.06 亿股， 环比增加 55.06%；成交额为 2085.03 亿元，环比增加 62.92%。本周北交所融资融券余 额为 74.98 亿元，较上周增加 7.56 亿元。本周：北交所 2 只新股上市：宏远股份、能之 光，上市首日涨跌幅分别为 358.02%、34 ...

Group 1 - AstraZeneca is optimistic about China's innovation potential and continues to expand its R&D presence in the country, investing $2.5 billion to establish a global strategic R&D center in Beijing [1] - In the first half of this year, the total import and export value of foreign enterprises in China reached 6.32 trillion yuan, a year-on-year increase of 2.4%, marking five consecutive quarters of growth [1] - From January to June, 30,014 new foreign-invested enterprises were established in China, representing a year-on-year increase of 11.7% [1] Group 2 - China's commitment to high-level opening-up provides solid policy support for foreign enterprises operating in the country [2] - Since 2013, China has revised its foreign investment negative list eight times, reducing restrictions from 190 to 29 nationwide and 27 in free trade zones, effectively eliminating restrictions in the manufacturing sector [3] - A "1+N" policy system has been established to stabilize foreign investment, enhancing China's attractiveness to foreign enterprises [3] Group 3 - China's large-scale market offers significant investment returns for foreign enterprises, with retail sales expected to exceed 50 trillion yuan this year, growing at an average annual rate of 5.5% [4] - Foreign investment returns in China have averaged around 9% in recent years, with many foreign companies reporting that the Chinese market remains a crucial source of revenue [4] - The recent China International Supply Chain Promotion Expo saw over 6,000 cooperation agreements signed, reflecting the immense demand from China's large market [4] Group 4 - China is promoting technological innovation to empower foreign enterprises, with a focus on integrating technological and industrial innovation [5] - In the first half of this year, actual foreign investment in high-tech industries reached 127.87 billion yuan, with significant growth in e-commerce services, chemical manufacturing, aerospace, and medical equipment sectors [5] - As China's innovation capabilities continue to improve, foreign enterprises are expected to gain more confidence and motivation for development [5] Group 5 - The attractiveness of the Chinese market for foreign investment is expected to strengthen across multiple dimensions, including policy, market size, and technological innovation [6]

Group 1 - The Chinese pharmaceutical industry is entering an innovative development phase, providing more motivation and assurance for AstraZeneca's innovation in China [1] - AstraZeneca announced a $2.5 billion investment to establish a global strategic R&D center in Beijing, aiming to enhance "China innovation" for global benefit [1] - AstraZeneca has two of its six global strategic R&D centers located in China, with a total R&D team exceeding 1,000 people, reflecting the company's commitment to the Chinese market [1] Group 2 - AstraZeneca has signed a strategic R&D cooperation agreement with China National Pharmaceutical Group, focusing on AI-driven drug research [2] - The company has established a $550 million fund to invest in local biopharmaceutical companies, having invested in 27 local enterprises [2] - AstraZeneca plans to introduce 20 new global drugs in China by 2030, having already brought over 40 innovative drugs to the market in the past 30 years [2] Group 3 - AstraZeneca is committed to promoting early diagnosis and treatment, addressing challenges faced by patients in rural areas [3] - The company has engaged with approximately 400 cities and 2,800 counties in China to ensure innovative drugs and quality medical resources reach more patients [3]

Group 1 - The core viewpoint of the articles highlights the challenges faced by BMW in the Chinese market, particularly due to price wars and declining brand value, necessitating a strategic shift in leadership and operations [2][6][19] - BMW has appointed Birgit Böhm-Wannenwetsch, a finance expert, as the new CEO of BMW Brilliance, indicating a focus on financial management and operational efficiency in response to market pressures [3][4][19] - The company has experienced a significant decline in sales, with 2022 sales dropping to 714,500 units, marking a downturn from previous years, and a corresponding decrease in revenue and profit [5][6][8] Group 2 - The automotive market in China has undergone substantial changes over the past three decades, with BMW initially benefiting from rapid growth but now facing a more competitive and challenging environment [9][14][33] - The shift in consumer preferences towards electric and smart vehicles poses a challenge for BMW, which has not traditionally excelled in these areas, leading to a need for adaptation and innovation [8][19][22] - The trend of appointing executives with financial and operational backgrounds is evident across the automotive industry, as companies seek to enhance their operational capabilities and adapt to the evolving market landscape [27][29][30] Group 3 - BMW's production capacity in China has expanded significantly, with the Shenyang plant reaching an annual capacity of 830,000 units, making it the largest single production base for BMW globally [12][13] - The company is increasingly leveraging Chinese R&D capabilities, with over 3,000 software engineers in China contributing to both local and global innovations, particularly in AI and electric vehicle technologies [25][24][23] - The automotive industry is witnessing a shift towards collaboration and innovation, with companies like BMW recognizing the importance of integrating local market demands into their global strategies [22][33][34]

Group 1 - The core viewpoint is that the Chinese private equity market is experiencing significant growth and attracting international capital despite global economic adjustments [1][2][8] - International capital is increasingly recognizing the long-term value of Chinese assets, shifting from short-term opportunities to long-term strategic investments [4][6] - The influx of foreign capital is driven by China's strong performance in innovation, particularly in sectors like biomedicine and artificial intelligence, which are now seen as global innovation hubs [3][5] Group 2 - The number of newly established funds in China's private equity market has rapidly increased since 2025, with active participation from local guiding funds and mother funds [2] - Foreign investors are showing renewed interest in China, with high-level executives frequently visiting to understand market dynamics and potential [2][3] - The Chinese government's supportive policies, including improved business environments and reduced entry barriers for foreign investments, are crucial for attracting international capital [5] Group 3 - The concept of "quality-price ratio" has become a key term among foreign investors, highlighting the competitive advantages of Chinese assets in terms of innovation quality and pricing [3] - The collaboration between foreign and Chinese companies is expected to enhance China's technological innovation and competitiveness on a global scale [6][8] - Challenges remain, such as the need for a more mature merger and acquisition market and addressing regional restrictions on foreign investments [7]